XENE

XENE

USD

Xenon Pharmaceuticals Inc. Common Shares

$39.090-0.650 (-1.636%)

Reaalajas hind

Healthcare
Biotehnoloogia
Kanada

Hinnagraafik

Loading Chart...

Põhinäitajad

Turunäitajad
Ettevõtte fundamentaalnäitajad
Kauplemisstatistika

Turunäitajad

Avatud

$39.740

Kõrge

$40.450

Madal

$37.625

Maht

0.18M

Ettevõtte fundamentaalnäitajad

Turukapitalisatsioon

3.0B

Tööstusharu

Biotehnoloogia

Riik

Canada

Kauplemisstatistika

Keskmine maht

0.79M

Börs

NGM

Valuuta

USD

52 nädala vahemik

Madal $26.74Praegune $39.090Kõrge $46

Seotud uudised

Analyst Upgrades

RBC Capital Maintains Outperform on Xenon Pharmaceuticals, Raises Price Target to $58

RBC Capital analyst Brian Abrahams maintains Xenon Pharmaceuticals with a Outperform and raises the price target from $55 to $58.

Vaata rohkem
RBC Capital Maintains Outperform on Xenon Pharmaceuticals, Raises Price Target to $58
Analyst Upgrades

Wells Fargo Maintains Overweight on Xenon Pharmaceuticals, Lowers Price Target to $44

Wells Fargo analyst Benjamin Burnett maintains Xenon Pharmaceuticals with a Overweight and lowers the price target from $48 to $44.

Vaata rohkem
Wells Fargo Maintains Overweight on Xenon Pharmaceuticals, Lowers Price Target to $44
Analyst Upgrades

Needham Reiterates Buy on Xenon Pharmaceuticals, Maintains $55 Price Target

Needham analyst Serge Belanger reiterates Xenon Pharmaceuticals with a Buy and maintains $55 price target.

Vaata rohkem
Needham Reiterates Buy on Xenon Pharmaceuticals, Maintains $55 Price Target
GlobeNewswire

Xenon to Report Q3 2025 Financial Results on November 3, 2025

VANCOUVER, British Columbia and BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and

Vaata rohkem
Xenon to Report Q3 2025 Financial Results on November 3, 2025